Alpha cognition announces partner china medical system has nda accepted in china for the review of zunveyl® (benzgalantamine) for alzheimer's disease

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition” [aci], or the “company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced china medical system holdings limited (cms) new drug application (nda) for zunveyl has been accepted by the national medical products administration of china (nmpa) for review for the treatment of mild-to-moderate alzheimer's dementia. “we are pl.
ACOG Ratings Summary
ACOG Quant Ranking